(WO201747872) The present invention relates to a porous nano structure and a method of manufacturing same. The porous nano structure exhibits excellent mechanical strength and has a wide specific surface area and is therefore useful as an absorbent, a vibration absorber, a sound absorber, a shock absorber, a catalyst support, a membrane for separation, etc., and can be applied to various technical fields such as electronics, composite materials, sensors, catalysts, energy storage materials, and ultra-high capacity storage batteries. In particular, the porous nano structure exhibits excellent hydrogen storage capability and is thus very useful as a hydrogen storage material.

(US9539550) An apparatus is presented that includes a body and a membrane. The body defines an externally hemispherical body portion with an orifice, as well as a channel passing through the body and terminating in the orifice. The membrane is formed at least in part of an elastomeric material and overlies a portion of the externally hemispherical body portion. The membrane defines a plurality of holes therein, and a plug that is inserted into the orifice and the channel. When submerged at the bottom of a wastewater treatment tank and in gaseous communication with a distribution conduit providing compressed gas, the apparatus may function to release bubbles into the wastewater. When the compressed gas is turned off, the apparatus acts as a check valve that stops water from entering the diffuser and the distribution conduit.

(TW201640998) 電磁波​遮蔽​薄膜​係​具備有：具有​凹凸​的​導電​性的​遮蔽​層(110)、及​被覆​凹凸​的​接著​劑​層(120)。 凹凸​的​最​大山​高度​的​值​係​大於​接著​劑​層(120)的​厚度。

(JP2016104072W) This photocatalyst is obtained from a nanostructure configured from multiple semiconductors. The nanostructure has a Type II band structure. For each semiconductor, the lower edge of the conduction band is more negative than the reduction potential of water and the upper edge of the valence band is more positive than the oxidation potential of water. (From WO2016104072 A1)

(IN2015MU04838) A precipitated silica is disclosed. Said precipitated silica has a BET/ CTAB in a range of 0.8-1.35; a DBP oil absorption in a range of 240-320 ml/100g; and a CDBP coef-ficient (DA) in range of 0.4 to 0.9.

(AU2015372560) Provided are antisense oligonucleotides targeted against bacterial genes involved in biochemical pathways and/or cellular processes, and related compositions and methods of using the oligonucleotides and compositions, alone or in combination with other antimicrobial agents, for instance, in the treatment of an infected mammalian subject. Embodiment's of the present disclosure relate, in part, to the discovery that the antisense targeting of bacterial genes involved in biochemical pathways and/or cellular processes can, inter alia, increase the antibiotic susceptibility of otherwise antibiotic-resistant pathogenic bacteria, and reduce the ability of certain pathogenic bacteria to grow.

(CA2972239) The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing proliferative diseases (e.g., cancers (e.g., leukemia, acute lymphoblastic leukemia, lymphoma, Burkitt's lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer, colorectal cancer), benign neoplasms, diseases associated with angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7)), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

(CA2972230) [Problem] To provide a pharmaceutical composition for treating various cancers in which mitochondrial complex I is involved, in particular, colon cancer, leukemia and/or malignant lymphoma. [Solution] With the intention of creating pharmaceutical compositions for treating various cancers, the inventors confirmed, on the basis of the result of intensive investigation, that pharmaceutical compositions, which contain specific bicyclic nitrogen-containing aromatic heterocyclic amide compounds having an AMPK activation effect and mitochondrial complex I inhibition effect as active ingredients, have a therapeutic effect on various cancers in which mitochondrial complex I is involved, in particular, colon cancer, leukemia and/or malignant lymphoma, thereby completing the present invention.

(CA2969301) A selective IL-6-trans-signalling inhibitor can be used to treat a variety of IL-6- mediated conditions, including inflammatory diseases and cancer. The inhibitor can safely be administered to humans at a variety of doses. Moreover, the inhibitor lessens deleterious effects associated with other IL-6 inhibitors such as lowering neutrophil counts, platelet counts and levels of C-reactive protein.